<DOC>
	<DOCNO>NCT00515801</DOCNO>
	<brief_summary>We aim demonstrate oral administration glibenclamide stimulate pancreatic glucagon secretion hypoglycemia insulin-deficient ( C-peptide negative ) patient type 1 diabetes compare type 1 diabetic patient residual insulin secretion ( C-peptide positive ) .</brief_summary>
	<brief_title>Sulfonylurea Effects Glucagon Regulation During Hypoglycemia Type 1 DM</brief_title>
	<detailed_description>The glucagon response insulin induce hypoglycemia rate glucose recovery monitor 10 C-peptide positive 10 C-Peptide negative patient type 1 DM follow application glibenclamide placebo randomize , single-blind , cross-over study . Cognitive function hypoglycemia without glibenclamide pretreatment secondary outcome .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Patients age 18 50 year Patients diagnose Cpeptide negative diabetes type 1 ( Cpeptide &lt; 200 pmol/L 6 min 1 mg glucagon i.v . plasma glucose concentration 5 11 mmol/l ) Patients diagnose Cpeptide positive diabetes type 1 ( Cpeptide &gt; 500 pmol/l 6 min 1 mg glucagon i.v . plasma glucose concentration 5 11 mmol/l ) Stable metabolic control ; HbA1c level &lt; 8.0 % without episodes antecedent severe hypoglycemia past four week Patients treat medication potentially interfere glucose metabolism , systemic steroid , immunosuppressive drug ( cyclosporine , tacrolimus , sirolimus ) , highly active antiretroviral therapy History coronary artery disease History epilepsy seizures Current smoker Any significant unstable hepatic , cardiac , pulmonary , renal , neurological , musculoskeletal , hematological endocrine disease . Pregnant breast feed woman Woman childbearing potential use reliable method birth control oral contraceptive IUD . Subjects refuse unable give write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>diabetes mellitus type 1</keyword>
	<keyword>hypoglycemia</keyword>
	<keyword>sulfonylurea</keyword>
	<keyword>glucagon</keyword>
</DOC>